Key words: ankylosing spondylitis, TNF, withdrawal, safety, efficacy
نویسندگان
چکیده
Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany; and Rheumatology Department, Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany. Xenofon Baraliakos, MD Uta Kiltz, MD Frank Heldmann, MD Joachim Sieper, MD Jürgen Braun, MD Please address correspondence to: Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Ruhr-University Bochum Landgrafenstraße 15, 44652 Herne, Germany. E-mail: [email protected] Received on August 17, 2013; accepted in revised form on August 26, 2013. Clin Exp Rheumatol 2013; 31 (Suppl. 78): S43-S46. © Copyright CliniCal and ExpErimEntal rhEumatology 2013.
منابع مشابه
Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondyl...
متن کاملEfficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis
Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with impact on axial skeleton, peripheral joints and enthuses, and it may result in severe disabilities of those parts. Tumor necrosis factor-α (TNF-α) inhibitors are considered as an effective treatment for patients with active AS. In this study, we conducted a network meta-analysis to compare the clinical outcomes of active AS p...
متن کاملSafety and clinical efficacy of golimumab in the treatment of arthritides
Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. This review covers the published clinical trial data on the use of golimumab for the approved indications mentioned above with respect to efficacy and safety. The various ongoing trial...
متن کاملEfficacy and safety of adalimumab in ankylosing spondylitis
Ankylosing spondylitis (AS) is the most common and most severe subtype of spondyloarthritis. It also may be an outcome of any of the other spondyloarthritis subtypes. AS preferentially affects the sacroiliac joints and the tip of the column, with a tendency to later ankylosis. Peripheral joints, enthesis, and other extra-articular involvement may be observed. Tumor necrosis factor (TNF) inhibit...
متن کاملWhy golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
متن کامل